Public offering

Global Ship Lease Announces Commencement of Public Offering of Class A Common Shares

Retrieved on: 
Thursday, January 21, 2021
Finance, Financial markets, Financial economics, Money, Initial public offering, Stock market, Corporate finance, Shelf registration, Security, New York Stock Exchange, Public offering, Par value

LONDON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE: GSL) (the Company) announced today that it intends to commence an underwritten public offering (the Offering) of its Class A common shares, par value $0.01 per share (the Common Shares).

Key Points: 
  • LONDON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE: GSL) (the Company) announced today that it intends to commence an underwritten public offering (the Offering) of its Class A common shares, par value $0.01 per share (the Common Shares).
  • The Company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent (15%) of the Common Shares offered in the Offering.
  • A shelf registration statement relating to the Common Shares was filed with the U.S. Securities and Exchange Commission (the SEC) and is effective.
  • Global Ship Leaseis a leading independent owner of containerships with a diversified fleet of mid-sized and smaller containerships.

Merus Announces Pricing of Public Offering of Common Shares

Retrieved on: 
Thursday, January 21, 2021
Initial public offering, Financial economics, Finance, Corporate finance, Money, Actuarial science, Underwriting, Public offering, Stock market

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, we and our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share.

Key Points: 
  • UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, we and our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $120 million.
  • In addition, Merus granted the underwriters a 30-day option to purchase up to an additional 727,272 common shares at the public offering price, less the underwriting discounts and commissions.
  • All of the shares in the offering are to be sold by Merus.

Versus Systems Inc. Announces Closing of $11.0 Million Public Offering

Retrieved on: 
Thursday, January 21, 2021
Initial public offering, Finance, Financial economics, Money, Financial markets, Stock market, Corporate finance, Actuarial science, Underwriting, Greenshoe, Subscription, Public offering

LOS ANGELES, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Versus Systems Inc. (Versus or the Company) (Nasdaq: VS) (CSE:VS) (FRANKFURT:BMVB) today announced that it closed its previously-announced public offering of 1,280,000 units.

Key Points: 
  • LOS ANGELES, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Versus Systems Inc. (Versus or the Company) (Nasdaq: VS) (CSE:VS) (FRANKFURT:BMVB) today announced that it closed its previously-announced public offering of 1,280,000 units.
  • Further, the underwriter has exercised in full its over-allotment option to purchase an additional 192,000 common shares, at the public offering price, less the underwriting discount.
  • The offering was priced at USD $7.50 per unit, for gross proceeds of USD $11,040,000, before deducting underwriting discounts and commissions and other offering expenses payable by Versus.
  • The Versus platform can be integrated into mobile, console, and PC games, as well as streaming media and mobile apps.

CareDx Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Thursday, January 21, 2021
Financial markets, Financial economics, Finance, Stock market, Corporate finance, Initial public offering, Underwriting, Stock, Public offering, Greenshoe, Red herring prospectus

The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $175,000,007.

Key Points: 
  • The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $175,000,007.
  • In addition, CareDx has granted the underwriters a 30 day option to purchase up to 288,461 additional shares of its common stock offered in the public offering on the same terms and conditions.
  • The offering is expected to close on or about January 25, 2021, subject to the satisfaction of customary closing conditions.
  • CareDx intends to use the net proceeds from this offering for working capital and general corporate purposes.

Editas Medicine Announces Pricing of Offering of Common Stock

Retrieved on: 
Thursday, January 21, 2021
Initial public offering, Editas Medicine, Gene therapy, Corporate finance, Financial economics, Public offering, Finance, Economy

CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.
  • Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock on the same terms and conditions.
  • All of the shares in the offering are to be sold by Editas Medicine.
  • Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision gene medicines for a broad class of diseases.

Chimerix Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Thursday, January 21, 2021
Financial economics, Corporate finance, Finance, Money, Stock market, Initial public offering, Actuarial science, Underwriting, Stock, Public offering

All of the shares to be sold in the offering are being sold by Chimerix.

Key Points: 
  • All of the shares to be sold in the offering are being sold by Chimerix.
  • The gross proceeds to Chimerix from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million.
  • In addition, Chimerix has granted the underwriters a30-dayoption to purchase up to an additional 1,764,750 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • H.C. Wainwright & Co. is acting as lead manager for the offering and JonesTrading is acting as co-manager for the offering.

Dream Finders Homes, Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Thursday, January 21, 2021
Initial public offering, Financial economics, Finance, Money, Financial markets, Stock market, Corporate finance, Greenshoe, Underwriting, Offering, Public offering, Subscription

JACKSONVILLE, Fla., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dream Finders Homes, Inc. (NASDAQ: DFH) announced today the pricing of its initial public offering of 9,600,000 shares of Class A common stock at the initial public offering price of $13.00 per share.

Key Points: 
  • JACKSONVILLE, Fla., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dream Finders Homes, Inc. (NASDAQ: DFH) announced today the pricing of its initial public offering of 9,600,000 shares of Class A common stock at the initial public offering price of $13.00 per share.
  • DFH expects to receive gross proceeds from the offering of approximately $124.8 million, before deducting underwriting discounts and estimated offering expenses, and excluding any exercise of the underwriters over-allotment option.
  • Builder Advisor Group, LLC and Zelman Partners LLC are joint lead managers for the offering.
  • This press release includes forward-looking statements regarding future events, including the expected closing of the offering and the expected use of net proceeds from the offering.

Athira Pharma Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Thursday, January 21, 2021
Financial economics, Finance, Corporate finance, Money, Initial public offering, Stock market, Athira Pharma, Underwriting, Public offering, Stock

BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (Athira), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share.

Key Points: 
  • BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (Athira), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share.
  • All of the shares of common stock are being offered by Athira.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira, are expected to be $90.0 million.
  • In addition, Athira has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price less underwriting discounts and commissions.

OCA Acquisition Corp. Announces Closing of $149.5 Million Initial Public Offering Wednesday, January 20, 2021

Retrieved on: 
Wednesday, January 20, 2021
Finance, Money, Financial markets, Corporate finance, Stock market, Initial public offering, Encodings, Ticker symbol, Public offering, NASDAQ, Warrant

The units began trading on The Nasdaq Capital Market ("Nasdaq") on Friday, January 15, 2021 under the ticker symbol "OCAXU".

Key Points: 
  • The units began trading on The Nasdaq Capital Market ("Nasdaq") on Friday, January 15, 2021 under the ticker symbol "OCAXU".
  • Each unit issued in the offering consists of one share of the Company's Class A common stock and one-half of one redeemable warrant.
  • Of the proceeds received from the consummation of the initial public offering and a simultaneous private placement of warrants, $151,742,500 (or $10.15 per unit sold in the public offering) was placed in the Companys trust account.
  • This press release contains statements that constitute "forward-looking statements," including with respect to the initial public offering and search for a business combination.

OncoSec Medical Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, January 20, 2021
Financial markets, Finance, Financial economics, Initial public offering, Stock market, U.S. Securities and Exchange Commission, SEC filings, Shelf registration, Prospectus, Registration statement, Public offering, Red herring prospectus

All of the shares to be sold in the offering will be offered by OncoSec.

Key Points: 
  • All of the shares to be sold in the offering will be offered by OncoSec.
  • OncoSec will file a preliminary prospectus supplement and accompanying base prospectus to its effective shelf registration statement on Form S-3 (File No.
  • 333-233447) with the U.S. Securities and Exchange Commission ("SEC") for the proposed public offering of its common stock.
  • The offering of these securities is being made under an effective shelf registration statement on file with the SEC.